NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Merck and certain of its officers and/or d ...

Purchasing stocks at the right time can maximize your return on investment, especially if you plan to buy and hold shares toward a short-term or medium-term financial goal. A stock’s P/E ratio can give you an immediate idea of whether a stock is trading at, below or above fair value. While the average P/E ratio varies by industry, most analysts consider a stock with a P/E ratio below 25 to be potentially undervalued by the market.   As the S&P 500 comes off its worst trading week of the year, a few of the i ...

Core Viewpoint - The article discusses the evolution of the HPV vaccine market in China, highlighting the challenges and changes in demand, pricing, and competition among vaccine manufacturers, particularly focusing on Merck's HPV vaccines and the emergence of domestic competitors [1][2][3]. Group 1: HPV Vaccine Market Dynamics - The HPV vaccine market in China has seen significant fluctuations, with Merck's four-valent and nine-valent vaccines initially experiencing high demand but later facing a decline in sales due to market saturation and competition from domestic vaccines [7][8][30]. - The introduction of domestic two-valent HPV vaccines at lower prices has intensified competition, leading to a price war that has drastically reduced the cost of HPV vaccines in China, with prices dropping below 200 yuan per dose [26][29]. - By August 2024, the price of the two-valent HPV vaccine had plummeted to 27.5 yuan per dose, reflecting the aggressive pricing strategies adopted by domestic manufacturers [29]. Group 2: Impact on Merck and Domestic Competitors - Merck's nine-valent HPV vaccine maintained a stable price due to its unique market position, but the increasing affordability of domestic vaccines has eroded its market share, particularly among cost-sensitive consumers [16][30]. - Despite Merck's strong sales growth in the past, with a 136.16% year-on-year increase in the number of nine-valent vaccines sold in 2023, the company faces challenges as the overall market for HPV vaccines in China is experiencing a decline in total issuance [30][33]. - Domestic manufacturers like Wantai and Watson have entered the market, leading to a significant shift in the competitive landscape, with both companies struggling to maintain profitability amid falling prices [29][36]. Group 3: Public Health Implications - The article emphasizes the public health significance of HPV vaccination, noting that cervical cancer remains a leading cause of cancer death among women globally, particularly in developing countries [42][44]. - The disparity in vaccine access and affordability highlights a broader issue of health equity, as lower-income populations are often unable to afford vaccines despite their necessity for cancer prevention [43][49]. - Initiatives for free or subsidized HPV vaccinations in certain regions, such as Inner Mongolia, demonstrate efforts to improve access and reduce the burden of cervical cancer, potentially setting a precedent for broader public health strategies [45][48].

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=132974&from=4 CLASS PERIOD: February 3, 2022 to Febru ...

Group 1: Market Overview - In 2023, 70 sample American companies generated over $3,000 billion in revenue from the Chinese market, contributing 12% to their global revenue[6] - The total global revenue of these companies exceeded $2.5 trillion, with a year-on-year growth of 1.1%[6] - The average revenue from the Chinese market for these companies was $4.39 billion, with a median of $2.16 billion[30] Group 2: Investment Trends - In 2023, the actual foreign investment in China reached $163.25 billion, ranking China as the second-largest recipient of foreign investment globally[15] - The number of newly established foreign-invested enterprises in China increased by 39.7% year-on-year, totaling 54,000[15] - The compound annual growth rate of U.S. investment in China from 2020 to 2023 was 13.5%, significantly higher than the overall growth rate of 3% for foreign investment in China[20] Group 3: Industry Performance - The consumer sector in China saw a compound annual growth rate of 19.4% from 2020 to 2023, double the global growth rate of 9.1%[50] - The healthcare sector in China grew by 16.8% during the same period, while the global healthcare market declined by 2%[59] - The information technology sector contributed the highest revenue share, averaging 25.7% of total revenue from the Chinese market[30]

Merck (MRK) ended the recent trading session at $92.25, demonstrating a +1.84% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.59%. Elsewhere, the Dow gained 1.39%, while the tech-heavy Nasdaq added 1.63%.Prior to today's trading, shares of the pharmaceutical company had lost 8.46% over the past month. This has lagged the Medical sector's loss of 0.63% and the S&P 500's loss of 2.42% in that time.Market participants will be closely following the f ...

Core Viewpoint - Merck's stock has declined 7.8% following the announcement of its fourth-quarter 2024 results and disappointing guidance for 2025, despite beating earnings and sales estimates [1][2]. Financial Performance - In Q4 2024, Merck's sales of the Gardasil vaccine declined by 17% due to weak demand in China, and sales of the new drug Winrevair also missed estimates [2]. - Merck's 2025 revenue guidance is projected between $64.1 billion and $65.6 billion, reflecting a year-over-year growth of 2% to 4%, which fell short of investor expectations [15][17]. - The earnings per share guidance for 2025 is set between $8.88 and $9.03, also below expectations [17]. Product Portfolio and Strengths - Keytruda, a PD-L1 inhibitor, is Merck's most significant product, accounting for approximately 50% of pharmaceutical sales and driving steady revenue growth [3][4]. - Merck is pursuing innovative strategies to enhance Keytruda's long-term growth, including combinations with other immuno-oncology drugs and a personalized mRNA therapeutic cancer vaccine in collaboration with Moderna [5][6]. Pipeline and Strategic Moves - Merck's pipeline has nearly tripled in the past three years, with several new vaccines and drugs expected to launch in the next five years, including the 21-valent pneumococcal conjugate vaccine, Capvaxive, and Winrevair [8][9]. - The company has made strategic acquisitions, including Eyebiotech Limited and Harpoon Therapeutics, to bolster its pipeline [7]. Challenges and Risks - Concerns are rising regarding Merck's reliance on Keytruda, especially with its patent expiration in 2028, and the need for diversification in its product lineup [10][11]. - Competitive pressure is increasing, particularly from Summit Therapeutics' ivonescimab, which has shown potential to outperform Keytruda in clinical studies [12]. - Sales of Gardasil have also been affected by economic conditions in China, leading to a temporary halt in shipments to manage inventory levels [13][14]. Market Performance - Merck's stock has underperformed, losing 28.7% over the past year compared to a 0.1% increase in the industry [18][19]. - The stock is currently trading below its 50-day and 200-day moving averages, indicating weak market sentiment [18]. Valuation - Merck's shares trade at a forward price/earnings ratio of 9.89, which is lower than the industry average of 17.48 and its five-year mean of 13.22, suggesting potential attractiveness from a valuation perspective [20].

Investment Rating - The report does not explicitly provide an investment rating for the industry or companies involved Core Insights - The report tracks the performance of American companies in China, highlighting that 70 sample companies generated over $2.5 trillion in global revenue in the 2023 fiscal year, with a stable contribution rate of 12% from the Chinese market, indicating resilience and growth potential [5][6][30] - The Chinese market is the second-largest market for 40% of the sample companies, with total revenue exceeding $300 billion in 2023, despite a year-on-year decline of 3.7% [6][30] - The report emphasizes the importance of adapting to local market demands and regulatory changes, with companies like Procter & Gamble integrating sustainability into their business models and Merck focusing on data security [6][30] Summary by Sections Section 1: Review of American Companies in China - In 2023, the number of newly established foreign-invested enterprises in China increased by 39.7%, with a total of 54,000 new companies [15][16] - The actual use of foreign capital reached $163.25 billion, ranking China as the second-largest recipient of foreign investment globally [15][16] - The report notes that the U.S. accounted for approximately 2.1% of the actual investment in China, ranking ninth among investment sources [16][19] Section 2: Industry Trends - The report categorizes industries into five main categories, with significant growth observed in the consumer sector, healthcare, and energy chemicals, while the industrial sector showed contraction [44][50] - The consumer sector in China has seen a compound annual growth rate (CAGR) of over 19% over the past four years, significantly outpacing global growth [55] - The healthcare sector is highlighted as a key growth area, with a 2% increase in revenue in China, contrasting with a global decline of 2% [59] Section 3: Outlook for American Companies in China - The report discusses the strategic actions of typical American companies in China, focusing on local market adaptation and innovation [6][30] - It identifies key market environments to watch, emphasizing the importance of regulatory compliance and sustainable business practices [6][30] Appendix: Revenue Data and Growth Rates - The report includes detailed revenue data for 70 sample companies, showing a median revenue of $2.16 billion and an average of $4.39 billion from the Chinese market [30][31] - It provides insights into revenue growth rates across various sectors, with notable increases in the semiconductor and consumer electronics industries [34][35][38]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) investors of a class action representing investors that bought securities between February 3, 2022 and February 3, 2025, inclusive (the "Class Period"). Merck investors have until April 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portno ...

Group 1 - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about Gardasil's expected revenue [1] - The class period for the lawsuit is from February 3, 2022, to February 3, 2025, during which Merck projected $11 billion in sales from Gardasil by 2030 [1] - On February 4, 2025, Merck announced it would not achieve the projected sales due to a halt in shipments to China, leading to a significant stock price drop of over 9% in one day [1] Group 2 - Shareholders are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs and receive updates on the case [2] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated Merck's stock price [3]